Glycerol for acute stroke
Abstract Background Brain oedema is a major cause of early death after stroke. A 10% solution of glycerol is a hyperosmolar agent that is claimed to reduce brain oedema. Objectives To determine whether intravenous glycerol treatment in acute stroke, either ischaemic or haemorrhagic, influences death rates and functional outcome in the short or long term, […]
Excitatory amino acid antagonists for acute stroke
Abstract Background Focal cerebral ischaemia causes release of excitatory amino acid (EAA) neurotransmitters, principally glutamate, with resultant over-stimulation of EAA receptors and downstream pathways. Excess glutamate release is a pivotal event in the evolution of irreversible ischaemic damage in animal models of ischaemia, and drugs that modulate glutamate action either by inhibiting its release, or […]
Anticoagulants versus antiplatelet agents for acute ischaemic stroke
Abstract Background Antiplatelet agents produce a small, but worthwhile benefit in long-term functional outcome and survival, and have become standard treatment for acute ischaemic stroke. Anticoagulants are often used as an alternative treatment, despite evidence that they are ineffective in producing long-term benefits. We wanted to review trials which have directly compared anticoagulants and antiplatelet […]
Lubeluzole for acute ischaemic stroke
Abstract Background Experimental studies have shown that ischaemic insults cause excess release of excitatory amino acid (EAA) neurotransmitters, particularly glutamate. Glutamate re-uptake is impaired under ischaemic conditions. In preclinical models of stroke, antagonists of excitatory amino acids or of glutamate release protect against ischaemic injury, even when administered after the ischaemic insult. Lubeluzole is a […]
Gangliosides for acute ischaemic stroke
Abstract Background Gangliosides may have a protective effect on the central and peripheral nervous systems. Objectives To assess the effect of exogenous gangliosides in acute ischaemic stroke. Search methods We searched the Cochrane Stroke Group trials register (last searched: May 2001) and contacted drug companies and main investigators of included trials. Selection criteria Randomised trials […]
Tirilazad for acute ischaemic stroke
Abstract Background Tirilazad mesylate is neuroprotective in experimental models of ischaemic stroke suggesting it might be of benefit clinically. Objectives To assess whether tirilazad mesylate is safe and effective at improving outcome in patients with acute ischaemic stroke. Search methods Trials of tirilazad were identified from searches of the Cochrane Stroke Group Trials Register (last […]